US Patent No: 7,989,431

Number of patents in Portfolio can not be more than 2000

2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity

ALSO PUBLISHED AS: 20090253647

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides compounds having the following general formula (I):

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA299

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Figler, Robert Alan Earlysville, VA 19 117
Linden, Joel M Charlottesville, VA 57 641
Macdonald, Timothy L Charlottesville, VA 91 381
Murphree, Lauren J Rockville, MD 12 72
Rieger, Jayson M Charlottesville, VA 82 423
Sullivan, Gail W Charlottesville, VA 41 599

Cited Art Landscape

Patent Info (Count) # Cites Year
 
UNIVERSITY OF VIRGINIA (20)
5,272,153 Method of inhibiting the activity of leukocyte derived cytokines 42 1992
5,877,180 Method for treating inflammatory diseases with A.sub.2a adenosine receptor agonists 65 1994
6,117,878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors 55 1998
6,303,619 Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors 29 1998
6,060,481 Method for improving insulin sensitivity using an adenosine receptor antagonist 26 1999
6,322,771 Induction of pharmacological stress with adenosine receptor agonists 39 1999
6,448,235 Method for treating restenosis with A2A adenosine receptor agonists 37 2000
6,514,949 Method compositions for treating the inflammatory response 35 2000
6,531,457 Methods and compositions for treating inflammatory response 27 2001
6,670,334 Method and compositions for treating the inflammatory response 28 2002
7,214,665 2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof 17 2002
7,427,606 Method to reduce inflammatory response in transplanted tissue 11 2004
* 7,605,143 agonist activity 9 2005
2006/0040,889 2-polycyclic propynyl adenosine analogs having A2A agonist activity 12 2005
* 7,378,400 Method to reduce an inflammatory response from arthritis 13 2005
2008/0009,460 METHOD TO TREAT SICKLE CELL DISEASE 10 2007
7,737,127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 5 2007
2007/0232,559 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 9 2007
2009/0162,282 SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS 6 2008
2010/0152,127 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 4 2010
 
PFIZER INC. (5)
6,326,359 Adenosine A2A receptor agonists as antiinflammatory agents 27 1999
6,350,735 Purine derivatives 15 2000
6,525,032 Purine derivatives 22 2001
6,624,158 Purine derivatives 14 2001
2003/0013,675 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases 25 2002
 
ADERIS PHARMACEUTICALS, INC. (4)
5,140,015 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 49 1990
5,278,150 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions 40 1992
RE36494 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 23 1993
6,339,072 Compositions and methods for preventing restenosis following revascularization procedures 20 2001
 
AVENTIS PHARMACEUTICALS PRODUCTS INC. (2)
5,364,862 Compounds having antihypertensive and anti-ischemic properties 59 1992
5,561,134 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties 49 1994
 
BIOCHEM PHARMA INC. (2)
5,756,706 Processes for the diastereoselective synthesis of nucleoside analogues 45 1994
5,696,254 Processes for the diastereoselective synthesis of nucleoside analogues 46 1994
 
MERCK FROSST CANADA LTD. (2)
6,020,339 Aryl furan derivatives as PDE IV inhibitors 39 1998
6,034,089 Aryl thiophene derivatives as PDE IV inhibitors 35 1998
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
5,298,508 Irreversible inhibitors of adenosine receptors 33 1992
6,545,002 Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors 27 2000
 
NEW YORK UNIVERSITY (2)
5,932,558 Adenosine receptor agonists for the promotion of wound healing 29 1996
6,020,321 Adenosine receptor agonists for the promotion of wound healing 25 1999
 
TROVIS PHARMACEUTICALS, LLC (2)
2009/0162,292 SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS 7 2008
2009/0280,059 SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS 8 2009
 
Yamasa Shoyu Kabushiki Kaisha (2)
4,956,345 2-alkynyladenosines as antihypertensive agents 54 1988
5,189,027 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases 52 1991
 
AKITA UNIVERSITY SCHOOL OF MEDICINE (1)
2008/0027,022 METHOD TO TREAT GASTRIC LESIONS 18 2007
 
AMERICAN HOME PRODUCTS CORPORATION (1)
5,124,455 Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents 75 1990
 
ANGELLO, PAUL S., 1858 PALISADES TERRACE DRIVE, LAKE OSWEGO, OREGON 97034 (1)
4,824,660 Method of determining the viability of tissue in an organism 33 1985
 
Burroughs Wellcome Co. (1)
4,879,296 Xanthine derivatives 50 1986
 
BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (1)
4,665,074 6-(polyfluoroalkoxyphenyl) pyridazinones, their compositions, synthesis and use 27 1985
 
CARDIOKINE, INC. (1)
5,998,386 Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue 42 1997
 
GLAXO WELLCOME INC. (1)
5,776,940 Phenylxanthine derivatives 27 1997
 
HEMISPHERX BIOPHARMA, INC. (1)
5,593,973 Treatment of viral hepatitis with mismatched dsRNA 19 1994
 
ICOS CORPORATION (1)
5,665,754 Substituted pyrrolidines 50 1993
 
Item Development AB (1)
5,731,296 Selective vasodilation by continuous adenosine infusion 39 1993
 
KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (1)
5,070,877 Novel method of myocardial imaging 64 1989
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
4,968,697 2-substituted adenosine 5'-carboxamides as antihypertensive agents 52 1989
 
PATENT FOUNDATION, VIRGINIA, UNIVERSITY OF (1)
6,232,297 Methods and compositions for treating inflammatory response 29 1999
 
PHARMACIA & UPJOHN S.P.A. (1)
5,593,976 New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds 16 1995
 
PUREF, LLC (1)
6,004,945 Use of adenosine compounds to relieve pain 25 1995
 
SCHERING CORPORATION (1)
5,593,975 Adenosine derivatives having A.sub.2 agonist activity 55 1995
 
SMITHKLINE BEECHAM CORPORATION (1)
6,407,076 Adenosine analogues and related method of treatment 14 2000
 
TEVA PHARMACEUTICAL INDUSTRIES LTD. (1)
5,565,462 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative 26 1994
 
The University of Patent Foundation (1)
5,854,081 Stable expression of human A.sub.2B adenosine receptors, and assays employing the same 34 1996
 
TOA EIYO LTD. (1)
6,936,596 Adenosine derivatives and use thereof 13 2001
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5,668,139 A1 adenosine receptor agonists and antagonists 22 1995
 
UNIVERSITY OF ROCHESTER, ROCHESTER, NEW YORK 14627, A NOT-FOR-PROFIT CORP. OF NEW YORK (1)
4,938,949 Treatment of damaged bone marrow and dosage units therefor 243 1988
 
UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION, THE, THE TOWERS OFFICE BUILDING, SUITE 6211, 1224 W. MAIN STREET, CHARLOTTESVILLE, VA 22903 A CORP OF VA (1)
5,096,906 Method of inhibiting the activity of leukocyte derived cytokines 80 1990
 
University of Virginia Patent Foundation and Adenosine Therapeutics, L.L.C. (1)
2009/0298,788 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY 6 2009
 
UNIVERSITY OF VIRGINIA, A CORP. OF DE (1)
4,965,271 Method of inhibiting the activity of leukocyte derived cytokines 74 1987
 
YAMASA CORPORATION (1)
6,387,889 Medicinal compositions for treating eye diseases 18 2001
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
UNIVERSITY OF VIRGINIA (3)
8,178,509 Method to treat sickle cell disease 0 2007
8,188,063 modulators to treat spinal cord injury 1 2007
8,158,604 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 0 2010
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Feb 2, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 2, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 2, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00